Cargando…

IV immunoglobulin confounds JC virus antibody serostatus determination

OBJECTIVE: To determine the impact of therapeutic infusion of IV immunoglobulin (IVIg) on John Cunningham virus antibody (JCV Ab) serostatus and level in serum. METHODS: We carried out a retrospective analysis of serum levels of JCV Ab among STRATIFY-2 trial enrollees from 2 multiple sclerosis cente...

Descripción completa

Detalles Bibliográficos
Autores principales: Kister, Ilya, Kuesters, Geoffrey, Chamot, Eric, Omari, Mirza, Dontas, Kim, Yarussi, Mary, Subramanyam, Meena, Herbert, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204227/
https://www.ncbi.nlm.nih.gov/pubmed/25340081
http://dx.doi.org/10.1212/NXI.0000000000000029
_version_ 1782340524964839424
author Kister, Ilya
Kuesters, Geoffrey
Chamot, Eric
Omari, Mirza
Dontas, Kim
Yarussi, Mary
Subramanyam, Meena
Herbert, Joseph
author_facet Kister, Ilya
Kuesters, Geoffrey
Chamot, Eric
Omari, Mirza
Dontas, Kim
Yarussi, Mary
Subramanyam, Meena
Herbert, Joseph
author_sort Kister, Ilya
collection PubMed
description OBJECTIVE: To determine the impact of therapeutic infusion of IV immunoglobulin (IVIg) on John Cunningham virus antibody (JCV Ab) serostatus and level in serum. METHODS: We carried out a retrospective analysis of serum levels of JCV Ab among STRATIFY-2 trial enrollees from 2 multiple sclerosis centers who were exposed to IVIg during the trial. For the subset of eligible patients, we estimated mean linear trends while on IVIg and after stopping IVIg with a linear mixed-effects model. RESULTS: The JCV Ab seropositivity rate in the group of patients that was recently exposed to IVIg was 100%, which is significantly higher than in the IVIg-naive population (58%, p < 0.001). The seropositivity rate in the patient group with remote IVIg exposure was similar to that in the IVIg-naive population (67%, p = 0.68, Fisher exact test). The slope of the linear trend line after stopping IVIg decreased significantly by −0.310 units per 100 days (95% confidence interval, −0.611 to −0.008; p = 0.04). CONCLUSIONS: Recent IVIg exposure is invariably associated with JCV Ab seropositivity. After stopping IVIg, JCV Ab levels tend to decrease with time, and seroreversion to innately Ab-negative status can occur.
format Online
Article
Text
id pubmed-4204227
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-42042272014-10-22 IV immunoglobulin confounds JC virus antibody serostatus determination Kister, Ilya Kuesters, Geoffrey Chamot, Eric Omari, Mirza Dontas, Kim Yarussi, Mary Subramanyam, Meena Herbert, Joseph Neurol Neuroimmunol Neuroinflamm Article OBJECTIVE: To determine the impact of therapeutic infusion of IV immunoglobulin (IVIg) on John Cunningham virus antibody (JCV Ab) serostatus and level in serum. METHODS: We carried out a retrospective analysis of serum levels of JCV Ab among STRATIFY-2 trial enrollees from 2 multiple sclerosis centers who were exposed to IVIg during the trial. For the subset of eligible patients, we estimated mean linear trends while on IVIg and after stopping IVIg with a linear mixed-effects model. RESULTS: The JCV Ab seropositivity rate in the group of patients that was recently exposed to IVIg was 100%, which is significantly higher than in the IVIg-naive population (58%, p < 0.001). The seropositivity rate in the patient group with remote IVIg exposure was similar to that in the IVIg-naive population (67%, p = 0.68, Fisher exact test). The slope of the linear trend line after stopping IVIg decreased significantly by −0.310 units per 100 days (95% confidence interval, −0.611 to −0.008; p = 0.04). CONCLUSIONS: Recent IVIg exposure is invariably associated with JCV Ab seropositivity. After stopping IVIg, JCV Ab levels tend to decrease with time, and seroreversion to innately Ab-negative status can occur. Lippincott Williams & Wilkins 2014-09-18 /pmc/articles/PMC4204227/ /pubmed/25340081 http://dx.doi.org/10.1212/NXI.0000000000000029 Text en © 2014 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Article
Kister, Ilya
Kuesters, Geoffrey
Chamot, Eric
Omari, Mirza
Dontas, Kim
Yarussi, Mary
Subramanyam, Meena
Herbert, Joseph
IV immunoglobulin confounds JC virus antibody serostatus determination
title IV immunoglobulin confounds JC virus antibody serostatus determination
title_full IV immunoglobulin confounds JC virus antibody serostatus determination
title_fullStr IV immunoglobulin confounds JC virus antibody serostatus determination
title_full_unstemmed IV immunoglobulin confounds JC virus antibody serostatus determination
title_short IV immunoglobulin confounds JC virus antibody serostatus determination
title_sort iv immunoglobulin confounds jc virus antibody serostatus determination
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204227/
https://www.ncbi.nlm.nih.gov/pubmed/25340081
http://dx.doi.org/10.1212/NXI.0000000000000029
work_keys_str_mv AT kisterilya ivimmunoglobulinconfoundsjcvirusantibodyserostatusdetermination
AT kuestersgeoffrey ivimmunoglobulinconfoundsjcvirusantibodyserostatusdetermination
AT chamoteric ivimmunoglobulinconfoundsjcvirusantibodyserostatusdetermination
AT omarimirza ivimmunoglobulinconfoundsjcvirusantibodyserostatusdetermination
AT dontaskim ivimmunoglobulinconfoundsjcvirusantibodyserostatusdetermination
AT yarussimary ivimmunoglobulinconfoundsjcvirusantibodyserostatusdetermination
AT subramanyammeena ivimmunoglobulinconfoundsjcvirusantibodyserostatusdetermination
AT herbertjoseph ivimmunoglobulinconfoundsjcvirusantibodyserostatusdetermination